Pasithea Therapeutics Corp.
NASDAQ Capital MarketTotal Valuation
Pasithea Therapeutics Corp. carries a market capitalization of 13.70M, placing it among publicly traded companies globally. Its enterprise value stands at -28.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.70M |
| Enterprise Value | -28.44M |
Share Statistics
Pasithea Therapeutics Corp. currently has 33.41M shares outstanding.
| Shares Outstanding | 33.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | -0.62 |
| P/OCF Ratio | -0.62 |
Financial Position
Pasithea Therapeutics Corp. maintains a current ratio of 26.25, meaning it holds 26.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 26.25 |
| Quick Ratio | 24.85 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -65.49 |
| Return on Assets (ROA) | -61.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Pasithea Therapeutics Corp.'s stock has declined approximately -45.14316% over the past 52 weeks. The 50-day moving average sits at 0.50, while the 200-day moving average is 0.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.14316% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.66 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -23.30M, while operating income came in at -23.96M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -23.96M |
| Pretax Income | -21.29M |
| Net Income | -21.29M |
| EBITDA | -23.30M |
| EBIT | -23.96M |
| Earnings Per Share (EPS) | -1.00 |
Balance Sheet
Total book value stands at 49.84M, with working capital of 46.41M providing operational flexibility.
| Cash & Cash Equivalents | 45.66M |
| Total Debt | N/A |
| Net Debt | -45.66M |
| Equity (Book Value) | 49.84M |
| Book Value Per Share | 1.49 |
| Working Capital | 46.41M |
Cash Flow
Pasithea Therapeutics Corp. produced -17.78M in operating cash flow over the past twelve months.
| Operating Cash Flow | -17.78M |
| Capital Expenditures | N/A |
| Free Cash Flow | -17.78M |
| FCF Per Share | -0.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -327.00 |
| FCF Yield | -162.02 |
Stock Splits
Pasithea Therapeutics Corp.'s most recent stock split took place on January 2, 2024 with a 20:1 split ratio.
| Last Split Date | 1/2/2024 |
| Split Ratio | 20:1 |
Scores
Pasithea Therapeutics Corp. posts an Altman Z-Score of 2.77, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.77 |